Podcast appearances and mentions of Joseph Diaz

Joseph Diaz joins the show to shares his insights on networking on LinkedIn and how to do it effectively without feeling slimy. On this episode, you'll hear about:

Blaine Henry is the founder of Fight-Library.com, and has contributed to RING Magazine, Sherdog.com, MMA Sucka, My MMA News, and Bloody Elbow. He currently hosts a weekly YouTube show covering the biggest fights within Boxing and MMA. Follow Blaine on

Robert Diaz is a Matchmaker, Boxing Manager, Advisor, & Boxing executive, most notably known for his time with Oscar De La Hoya's Golden Boy Promotions. He is an inductee into the West Coast Boxing Hall-of-Fame and now works with various promotions, fighters, and boxing representatives all over the world. You can follow him on Twitter @Micheladatime. The bell has rung and The Last Round Boxing Podcast is back with another knockout episode! We're unpacking the aftermath of a seismic fight weekend that has set the boxing world ablaze. Ryan Garcia's stunning victory over Devin Haney has catapulted him into the stratosphere of stardom, and we're here to break down every jab, hook, and uppercut that led to this career-defining moment. Joining us in our corner is the mastermind matchmaker and boxing advisor, Roberto Diaz, for a deep dive into the mechanics behind the scenes and his take on the future of boxing's new golden boy, Ryan Garcia. Diaz spills the beans on the strategic matchmaking, the intense pressure, and the electric atmosphere that has everyone talking. But that's not all – we're also setting our sights on the future with a preview of the highly anticipated Canelo vs. Munguia showdown. Will Canelo continue his reign, or will Munguia's hunger for glory tip the scales? Plus, we're dissecting the return of Abner Mares against Leo Santa Cruz and the potential impact of Saudi Arabia's General Entertainment Authority staging a fight in LA. Tighten your gloves and get ready for an episode packed with expert analysis, insider stories, and the pulse of the sweet science. It's The Last Round, and we're just getting started! Don't forget to rate us 5 STARS and hit that follow/subscription button to help us climb the podcast rankings and bring you even bigger fights and guests each week! Find all things The Last Round: https://linktr.ee/TheLastRound

#josephdiaz #goldenboypromotions #oscardelahoya ️️️☎️ Joseph Diaz Jr. vs. Jesus “Ricky” Perez, Adrien Curiel vs. Sivenathi Nontshinga II Previews and Predictions❗️

Jaxxon Podcast Presented by Jaxxon JewelryShop the best Men's chains

In April, I did an AMA (Ask Me Anything) on LinkedIn, and the questions were SO juicy

In another ram-packed episode, Lukasz takes you through the week's boxing, including a hot-of-the-presses breakdown of Kenshiro's magnificent performance against Hiroto Kyoguchi, a look at how Jamaine Ortiz performed so much better than expected against Lomachenko, and more. For our followers and any new readers, read an update on our ongoing appeal for help for Iggy here: https://www.thefight-site.com/home/reader-notice-fundraiser-update Follow Lukasz on Twitter: https://twitter.com/craftyboxing Follow us on Twitter: https://twitter.com/FightSitedotcom Check out our written content on the website: https://www.thefight-site.com/ Support us directly on Patreon for exclusive content and access to the discord: https://www.patreon.com/fightsite We now have exclusive merchandise at teespring.com/stores/the-fight-site-shop

☎️Joseph Diaz Jr. vs. William Zepeda

Go online to PeerView.com/HWY860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Chronic spontaneous urticaria (CSU) is defined by the presence of recurrent urticaria, angioedema, or both, for a period of 6 weeks or longer. There are several theories regarding the pathogenesis of CSU, none of which have been conclusively established. CSU is a self-limited disorder in most patients, with an average duration of disease of 2 to 5 years; although active CSU significantly impairs quality of life. Second-generation H1 antihistamines (sgAHs) in standard dose are effective in less than 50% of CSU patients. Increasing the dose of sgAHs improves treatment responses; however, every third to fourth patient will still remain symptomatic. Omalizumab, an anti-IgE monoclonal antibody, may also be used for effective treatment, as well as cyclosporine. The current guideline-recommended treatment algorithm, though useful, is not perfect. The treatment of patients with CSU should be individualized and take into account the likelihood of patients to respond to therapy, based on predictors of response. By choosing treatment options tailored to a patient's clinical or biochemical characteristics, treatments that are less likely to be effective may be avoided. In this activity, based on a live symposium held at the AAD Annual Meeting in Boston, a panel of experts will discuss the selection of adequate and relevant tests for the diagnostic workup in CSU and novel treatment options for CSU in the context of mechanism of action, efficacy, and safety. In addition, they will take a closer look at treating CSU in accordance with current evidence and expert recommendations, recognizing that as the era of personalized treatment emerges, the best use for newer agents will be achieved with a deeper understanding of both the phenotype and endotype of each CSU patient. Upon completion of this activity, participants should be better able to: Select adequate and relevant tests for the diagnostic workup in chronic spontaneous urticaria (CSU) by obtaining a thorough medical history, Discuss how recent insights into the pathogenesis of CSU have led to the development of novel therapeutic targets, Describe novel treatment options for CSU in the context of mechanism of action, efficacy, and safety, Treat CSU in accordance with current evidence and expert recommendations, recognizing that as the era of personalized treatment emerges, the best use for newer agents will be achieved with a deeper understanding of both the phenotype and endotype of each CSU patient.

Go online to PeerView.com/HWY860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Chronic spontaneous urticaria (CSU) is defined by the presence of recurrent urticaria, angioedema, or both, for a period of 6 weeks or longer. There are several theories regarding the pathogenesis of CSU, none of which have been conclusively established. CSU is a self-limited disorder in most patients, with an average duration of disease of 2 to 5 years; although active CSU significantly impairs quality of life. Second-generation H1 antihistamines (sgAHs) in standard dose are effective in less than 50% of CSU patients. Increasing the dose of sgAHs improves treatment responses; however, every third to fourth patient will still remain symptomatic. Omalizumab, an anti-IgE monoclonal antibody, may also be used for effective treatment, as well as cyclosporine. The current guideline-recommended treatment algorithm, though useful, is not perfect. The treatment of patients with CSU should be individualized and take into account the likelihood of patients to respond to therapy, based on predictors of response. By choosing treatment options tailored to a patient's clinical or biochemical characteristics, treatments that are less likely to be effective may be avoided. In this activity, based on a live symposium held at the AAD Annual Meeting in Boston, a panel of experts will discuss the selection of adequate and relevant tests for the diagnostic workup in CSU and novel treatment options for CSU in the context of mechanism of action, efficacy, and safety. In addition, they will take a closer look at treating CSU in accordance with current evidence and expert recommendations, recognizing that as the era of personalized treatment emerges, the best use for newer agents will be achieved with a deeper understanding of both the phenotype and endotype of each CSU patient. Upon completion of this activity, participants should be better able to: Select adequate and relevant tests for the diagnostic workup in chronic spontaneous urticaria (CSU) by obtaining a thorough medical history, Discuss how recent insights into the pathogenesis of CSU have led to the development of novel therapeutic targets, Describe novel treatment options for CSU in the context of mechanism of action, efficacy, and safety, Treat CSU in accordance with current evidence and expert recommendations, recognizing that as the era of personalized treatment emerges, the best use for newer agents will be achieved with a deeper understanding of both the phenotype and endotype of each CSU patient.

Go online to PeerView.com/HWY860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Chronic spontaneous urticaria (CSU) is defined by the presence of recurrent urticaria, angioedema, or both, for a period of 6 weeks or longer. There are several theories regarding the pathogenesis of CSU, none of which have been conclusively established. CSU is a self-limited disorder in most patients, with an average duration of disease of 2 to 5 years; although active CSU significantly impairs quality of life. Second-generation H1 antihistamines (sgAHs) in standard dose are effective in less than 50% of CSU patients. Increasing the dose of sgAHs improves treatment responses; however, every third to fourth patient will still remain symptomatic. Omalizumab, an anti-IgE monoclonal antibody, may also be used for effective treatment, as well as cyclosporine. The current guideline-recommended treatment algorithm, though useful, is not perfect. The treatment of patients with CSU should be individualized and take into account the likelihood of patients to respond to therapy, based on predictors of response. By choosing treatment options tailored to a patient's clinical or biochemical characteristics, treatments that are less likely to be effective may be avoided. In this activity, based on a live symposium held at the AAD Annual Meeting in Boston, a panel of experts will discuss the selection of adequate and relevant tests for the diagnostic workup in CSU and novel treatment options for CSU in the context of mechanism of action, efficacy, and safety. In addition, they will take a closer look at treating CSU in accordance with current evidence and expert recommendations, recognizing that as the era of personalized treatment emerges, the best use for newer agents will be achieved with a deeper understanding of both the phenotype and endotype of each CSU patient. Upon completion of this activity, participants should be better able to: Select adequate and relevant tests for the diagnostic workup in chronic spontaneous urticaria (CSU) by obtaining a thorough medical history, Discuss how recent insights into the pathogenesis of CSU have led to the development of novel therapeutic targets, Describe novel treatment options for CSU in the context of mechanism of action, efficacy, and safety, Treat CSU in accordance with current evidence and expert recommendations, recognizing that as the era of personalized treatment emerges, the best use for newer agents will be achieved with a deeper understanding of both the phenotype and endotype of each CSU patient.

Go online to PeerView.com/HWY860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Chronic spontaneous urticaria (CSU) is defined by the presence of recurrent urticaria, angioedema, or both, for a period of 6 weeks or longer. There are several theories regarding the pathogenesis of CSU, none of which have been conclusively established. CSU is a self-limited disorder in most patients, with an average duration of disease of 2 to 5 years; although active CSU significantly impairs quality of life. Second-generation H1 antihistamines (sgAHs) in standard dose are effective in less than 50% of CSU patients. Increasing the dose of sgAHs improves treatment responses; however, every third to fourth patient will still remain symptomatic. Omalizumab, an anti-IgE monoclonal antibody, may also be used for effective treatment, as well as cyclosporine. The current guideline-recommended treatment algorithm, though useful, is not perfect. The treatment of patients with CSU should be individualized and take into account the likelihood of patients to respond to therapy, based on predictors of response. By choosing treatment options tailored to a patient's clinical or biochemical characteristics, treatments that are less likely to be effective may be avoided. In this activity, based on a live symposium held at the AAD Annual Meeting in Boston, a panel of experts will discuss the selection of adequate and relevant tests for the diagnostic workup in CSU and novel treatment options for CSU in the context of mechanism of action, efficacy, and safety. In addition, they will take a closer look at treating CSU in accordance with current evidence and expert recommendations, recognizing that as the era of personalized treatment emerges, the best use for newer agents will be achieved with a deeper understanding of both the phenotype and endotype of each CSU patient. Upon completion of this activity, participants should be better able to: Select adequate and relevant tests for the diagnostic workup in chronic spontaneous urticaria (CSU) by obtaining a thorough medical history, Discuss how recent insights into the pathogenesis of CSU have led to the development of novel therapeutic targets, Describe novel treatment options for CSU in the context of mechanism of action, efficacy, and safety, Treat CSU in accordance with current evidence and expert recommendations, recognizing that as the era of personalized treatment emerges, the best use for newer agents will be achieved with a deeper understanding of both the phenotype and endotype of each CSU patient.

Go online to PeerView.com/HWY860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Chronic spontaneous urticaria (CSU) is defined by the presence of recurrent urticaria, angioedema, or both, for a period of 6 weeks or longer. There are several theories regarding the pathogenesis of CSU, none of which have been conclusively established. CSU is a self-limited disorder in most patients, with an average duration of disease of 2 to 5 years; although active CSU significantly impairs quality of life. Second-generation H1 antihistamines (sgAHs) in standard dose are effective in less than 50% of CSU patients. Increasing the dose of sgAHs improves treatment responses; however, every third to fourth patient will still remain symptomatic. Omalizumab, an anti-IgE monoclonal antibody, may also be used for effective treatment, as well as cyclosporine. The current guideline-recommended treatment algorithm, though useful, is not perfect. The treatment of patients with CSU should be individualized and take into account the likelihood of patients to respond to therapy, based on predictors of response. By choosing treatment options tailored to a patient's clinical or biochemical characteristics, treatments that are less likely to be effective may be avoided. In this activity, based on a live symposium held at the AAD Annual Meeting in Boston, a panel of experts will discuss the selection of adequate and relevant tests for the diagnostic workup in CSU and novel treatment options for CSU in the context of mechanism of action, efficacy, and safety. In addition, they will take a closer look at treating CSU in accordance with current evidence and expert recommendations, recognizing that as the era of personalized treatment emerges, the best use for newer agents will be achieved with a deeper understanding of both the phenotype and endotype of each CSU patient. Upon completion of this activity, participants should be better able to: Select adequate and relevant tests for the diagnostic workup in chronic spontaneous urticaria (CSU) by obtaining a thorough medical history, Discuss how recent insights into the pathogenesis of CSU have led to the development of novel therapeutic targets, Describe novel treatment options for CSU in the context of mechanism of action, efficacy, and safety, Treat CSU in accordance with current evidence and expert recommendations, recognizing that as the era of personalized treatment emerges, the best use for newer agents will be achieved with a deeper understanding of both the phenotype and endotype of each CSU patient.

Go online to PeerView.com/HWY860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Chronic spontaneous urticaria (CSU) is defined by the presence of recurrent urticaria, angioedema, or both, for a period of 6 weeks or longer. There are several theories regarding the pathogenesis of CSU, none of which have been conclusively established. CSU is a self-limited disorder in most patients, with an average duration of disease of 2 to 5 years; although active CSU significantly impairs quality of life. Second-generation H1 antihistamines (sgAHs) in standard dose are effective in less than 50% of CSU patients. Increasing the dose of sgAHs improves treatment responses; however, every third to fourth patient will still remain symptomatic. Omalizumab, an anti-IgE monoclonal antibody, may also be used for effective treatment, as well as cyclosporine. The current guideline-recommended treatment algorithm, though useful, is not perfect. The treatment of patients with CSU should be individualized and take into account the likelihood of patients to respond to therapy, based on predictors of response. By choosing treatment options tailored to a patient's clinical or biochemical characteristics, treatments that are less likely to be effective may be avoided. In this activity, based on a live symposium held at the AAD Annual Meeting in Boston, a panel of experts will discuss the selection of adequate and relevant tests for the diagnostic workup in CSU and novel treatment options for CSU in the context of mechanism of action, efficacy, and safety. In addition, they will take a closer look at treating CSU in accordance with current evidence and expert recommendations, recognizing that as the era of personalized treatment emerges, the best use for newer agents will be achieved with a deeper understanding of both the phenotype and endotype of each CSU patient. Upon completion of this activity, participants should be better able to: Select adequate and relevant tests for the diagnostic workup in chronic spontaneous urticaria (CSU) by obtaining a thorough medical history, Discuss how recent insights into the pathogenesis of CSU have led to the development of novel therapeutic targets, Describe novel treatment options for CSU in the context of mechanism of action, efficacy, and safety, Treat CSU in accordance with current evidence and expert recommendations, recognizing that as the era of personalized treatment emerges, the best use for newer agents will be achieved with a deeper understanding of both the phenotype and endotype of each CSU patient.

Go online to PeerView.com/HWY860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Chronic spontaneous urticaria (CSU) is defined by the presence of recurrent urticaria, angioedema, or both, for a period of 6 weeks or longer. There are several theories regarding the pathogenesis of CSU, none of which have been conclusively established. CSU is a self-limited disorder in most patients, with an average duration of disease of 2 to 5 years; although active CSU significantly impairs quality of life. Second-generation H1 antihistamines (sgAHs) in standard dose are effective in less than 50% of CSU patients. Increasing the dose of sgAHs improves treatment responses; however, every third to fourth patient will still remain symptomatic. Omalizumab, an anti-IgE monoclonal antibody, may also be used for effective treatment, as well as cyclosporine. The current guideline-recommended treatment algorithm, though useful, is not perfect. The treatment of patients with CSU should be individualized and take into account the likelihood of patients to respond to therapy, based on predictors of response. By choosing treatment options tailored to a patient's clinical or biochemical characteristics, treatments that are less likely to be effective may be avoided. In this activity, based on a live symposium held at the AAD Annual Meeting in Boston, a panel of experts will discuss the selection of adequate and relevant tests for the diagnostic workup in CSU and novel treatment options for CSU in the context of mechanism of action, efficacy, and safety. In addition, they will take a closer look at treating CSU in accordance with current evidence and expert recommendations, recognizing that as the era of personalized treatment emerges, the best use for newer agents will be achieved with a deeper understanding of both the phenotype and endotype of each CSU patient. Upon completion of this activity, participants should be better able to: Select adequate and relevant tests for the diagnostic workup in chronic spontaneous urticaria (CSU) by obtaining a thorough medical history, Discuss how recent insights into the pathogenesis of CSU have led to the development of novel therapeutic targets, Describe novel treatment options for CSU in the context of mechanism of action, efficacy, and safety, Treat CSU in accordance with current evidence and expert recommendations, recognizing that as the era of personalized treatment emerges, the best use for newer agents will be achieved with a deeper understanding of both the phenotype and endotype of each CSU patient.

Go online to PeerView.com/HWY860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Chronic spontaneous urticaria (CSU) is defined by the presence of recurrent urticaria, angioedema, or both, for a period of 6 weeks or longer. There are several theories regarding the pathogenesis of CSU, none of which have been conclusively established. CSU is a self-limited disorder in most patients, with an average duration of disease of 2 to 5 years; although active CSU significantly impairs quality of life. Second-generation H1 antihistamines (sgAHs) in standard dose are effective in less than 50% of CSU patients. Increasing the dose of sgAHs improves treatment responses; however, every third to fourth patient will still remain symptomatic. Omalizumab, an anti-IgE monoclonal antibody, may also be used for effective treatment, as well as cyclosporine. The current guideline-recommended treatment algorithm, though useful, is not perfect. The treatment of patients with CSU should be individualized and take into account the likelihood of patients to respond to therapy, based on predictors of response. By choosing treatment options tailored to a patient's clinical or biochemical characteristics, treatments that are less likely to be effective may be avoided. In this activity, based on a live symposium held at the AAD Annual Meeting in Boston, a panel of experts will discuss the selection of adequate and relevant tests for the diagnostic workup in CSU and novel treatment options for CSU in the context of mechanism of action, efficacy, and safety. In addition, they will take a closer look at treating CSU in accordance with current evidence and expert recommendations, recognizing that as the era of personalized treatment emerges, the best use for newer agents will be achieved with a deeper understanding of both the phenotype and endotype of each CSU patient. Upon completion of this activity, participants should be better able to: Select adequate and relevant tests for the diagnostic workup in chronic spontaneous urticaria (CSU) by obtaining a thorough medical history, Discuss how recent insights into the pathogenesis of CSU have led to the development of novel therapeutic targets, Describe novel treatment options for CSU in the context of mechanism of action, efficacy, and safety, Treat CSU in accordance with current evidence and expert recommendations, recognizing that as the era of personalized treatment emerges, the best use for newer agents will be achieved with a deeper understanding of both the phenotype and endotype of each CSU patient.

In this episode, Amber covers the devastating murder of child star, Judith Barsi. Judith, or Judy as she was known, was born June 6, 1978. She began her career in television, making appearances in commercials and television series as well as in the film Jaws: The Revenge, she provided voices for animated characters in “All Dogs Go To Heaven” and “The Land Before Time” as Ducky, where she was known for her famous line of "Yep, yep yep". She and her mother, Maria, were killed in July 1988 in a double murder-suicide committed in their home by her father, József Barsi.Amber was drinking Browne Family Rose Grenache, and she really enjoyed it.Sources:www.mirror.co.uk. /  “Haunting tale of child star Judith Barsi who was shot dead by her dad aged 10 after years of abuse” Judith Barsi was murdered at the age of just 10 by her own father, who also killed her mother bfore turning the gun on himself / Molly Pike / July 25, 2020www.medium.com / “The Murder of Child Star Judith Barsi” / Lori Johnston / June 7, 2020www.the-sun.com / Ghost of Jaws child star Judith Barsi ‘Is HAUNTING LA home 32 years after she was brutally murdered by drunken dad' / Fionnuala O'Leary / October 6, 2020www.truecrimeedition.com / “The Short Life and Murder of Judith Barsi” / May 25, 2021www.latimes.com / “A Script of Fear: Repeated Threats by Father of Child Actress Carried to Tragic End” / John Johnson & Gabe Fuentes / August 7, 1988www.en.wikipedia.orgThen Erika covers the chaotic killings of Keith Hunter Jesperson a.k.a. “The Happy Face Killer”.  In January of 1990, he would murder his first victim Taunja Bennett in Portland, Oregon.  Her body would be discovered and then all of a sudden, with an anonymous tip to police by Laverne Pavlinac, things started to seem like they were coming together for the investigation. Laverne started with blaming her way younger boyfriend John Sosnovske and then after changing her story a few too many times, she ends up implicating herself.  So…while Pavlinac and Sosnovske are dragging the investigation through the ringer for something they didn't even do, Keith is out wreaking havoc and would end up murdering even more women. Erika was back to drinking her Yellow Tail Chardonnay, so we know how that was. LOLSources:www.abcnews.com / ‘Happy Face Killer' case tapes reveal the lengths woman went to frame boyfriend-Meanwhile, the real killer carried out a series of murders over five years /Joseph Diaz, Scott Engel, Emily Wynn, Jenner Smith & Lauren Effron / Nov.4, 2021www.abcnews.com / ‘Happy Face Killer's' daughter believes he would kill again if released-Serial killer Keith Jesperson has been in prison since 1995 / Jospeh Diaz & Lauren Effron / Nov. 5, 2021www.allthatisinteresting.com / The Girsly Story Of The Happy Face Killer, The Long-Haul Trucker Who Murdered Women Across America / Kaleena Fraga, Checked by Adam Farley / December 7, 2021www.criminalminds.fandom.com / Keith Jesperson, a.k.a. “The Happy Face Killer”, is a Canadian-born American

Joe Diaz is the co-founder of AFAR, the leading media brand for and by travelers who care. Founded by Joe and Greg Sullivan in 2009, AFAR inspires, guides, and empowers travelers to have enriching experiences that make a positive impact on the world. Through its flagship magazine, AFAR, its digital platform, afar.com, its non-profit foundation, Learning Afar, and its deep commitment to sustainability as a public benefit company, AFAR fulfills its mission by enriching the lives of travelers, directly supporting and contributing to the communities visited, and minimizing the negative effects on our planet. AFAR is currently the third fastest growing media company (+2.5MM MUV's)  with the third most affluent audience (median HH Net Worth $1.1MM)  in all of measured media, according to IPSOS. Check out afar.com and sign up for AFAR's newsletters. On this episode, Joe shares his one way ticket to "travel as a force for good". He also highlights AFAR's origins and offerings, how taxi drivers are a portal to spontaneity and surprise, and how it's not about the number of countries you've been to - but the number of kitchen tables you've sat at in those countries. Joe is just one of the engaging personalities featured on The One Way Ticket Show, where Host Steven Shalowitz explores with his guests where they would go if given a one way ticket, no coming back. Their destinations may be in the past, present, future, real, imaginary or a state of mind. Steven's guests have included: Nobel Peace Prize Winner, President Jose Ramos-Horta; Legendary Talk Show Host, Dick Cavett; Law Professor, Alan Dershowitz; Fashion Expert, Tim Gunn; Broadcast Legend, Charles Osgood; International Rescue Committee President & CEO, David Miliband; Former Senator, Joe Lieberman; Playwright, David Henry Hwang; Journalist-Humorist-Actor, Mo Rocca; SkyBridge Capital Founder & Co-Managing Partner, Anthony Scaramucci; Abercrombie & Kent Founder, Geoffrey Kent; Travel Expert, Pauline Frommer, as well as leading photographers, artists, chefs, writers, intellectuals, etc.

Gran actuación del pitbull Cruz ante Gervonta Davis!!!Devin Haney cumple el tramite ante Jo Jo Diaz!Teofimo Lopez a aun golpe de perder la vida !George Kambosos  aun no define su 2022Gilberto Ramirez esta listo para cerrar el año!! 

Fritz and Franco took in the fights from DAZN and ESPN+, starting with Charlie Edwards vs Jacob Barreto in East London at York Hall. They also broke down Isaac Lowe vs Luis Alberto Lopez and all of the knockdowns. Then the boys break down Chicago's very own, Jessica McCaskill vs Kandi Wyatt. Next was Carlos Diaz vs Montana Love and then Devin Haney vs Joseph "Jojo" Diaz. Listen as Fritz and Franco break it all down, as always, with a sense of humor.

Join us as we dive into this weekends boxing bouts! We start the episode by analyzing the Michael Hunter vs Jerry Forrest (rematch) bout; Devin Haney vs Joseph Diaz; Sergiy Derevyanchenko vs Carlos Adames; and the biggest bout of the night Gervonta Davis vs Isaac  Cruz! Tune in to hear all the boxing news and rumors! For the first time in Boxing Talk history, we preview a total of nine boxing bouts in an episode: Donnie Nietes vs Norbelto Jimenez; John Riel Casimero vs Paul Butler; Shavkatdzhon Rakhimov vs Railway Oladosu; Dmitry Bivol vs Umar Salamov; Magomed Kurbanov vs Patrick Teixeira; Jesse Hart vs. David Murray; Kudratillo Abdukakhorov vs Cody Crowley; Nonito Donaire vs Reymart Gaballo; and the most anticipated fight between Vasyl Lomachenko vs Richard Commey. Follow us on social media: Instagram - boxingtalkpodcastTwitter - BoxingTalkPod "We're not experts, just friends!" As always, thank you for listening! 

Coach Jason returns to talk Devin Haney (c) vs. Joseph Diaz, Gervonta Davis (c) vs. Isaac Cruz, Sergio Pettis (c) vs. Kyoji Horiguchi, Rob Font vs. José Aldo, Rafael Fiziev vs. Brad Riddell, and Charles Oliveira (c) vs. Dustin Poirier. Veteran to Champion: Charles Oliveira: https://www.patreon.com/posts/59402856 We can't continue to produce important episodes like this one without your solidarity. There is no Southpaw network without your financial support. In return, not only do you help produce our shows but you also get access to more great content. It's mutual aid. Find our Patreon, swag, and other ways to support us at: https://www.southpawpod.com Find Jason on Twitter: @JasonSargus You can find Southpaw on Facebook, Twitter, and Instagram: @SouthpawPod

Phones: 1-213-267-7787 (USA), +442081036051 (UK) On episode 293 of The Neutral Corner boxing podcast, host Michael Montero is joined by promoter Terri Moss, who will host another club show in Atlanta this Saturday. Montero will be doing ringside commentary for the broadcast of the show on the WBC Live Channel. Later, Montero reviews the closer-than-expected lightweight fight between Gervonta Davis and Isaac Cruz, and Devin Haney's win over Joseph Diaz. Montero also gives a detailed breakdown of the loaded fight schedule this weekend, including Vasiliy Lomachenko facing Richard Commey. https://youtu.be/IjELQ54_eLk

Join this channel to get access to perks:https://www.youtube.com/channel/UCcKT39KR_e3ZliHe4cyC06A/joinOne Free Month of Dazn On TBV http://bit.ly/ThaBoxingVoicexDAZNhttps://www.patreon.com/ThaboxingvoiceBUY THA BOXING VOICE T-SHIRT HERE http://thaboxingvoice.com/storePLEASE SUPPORT!!! SUBSCRIBE, SHARE & LIKEPlease check out our Facebook page and hit the like button. https://www.facebook.com/Thaboxingvoiceradio GOOGLE PLUS https://plus.google.com/107960664507143008932/posts?tab=XXiWeb Sitehttp://thaboxingvoice.com/Radio show: http://www.blogtalkradio.com/thaboxingvoiceradioTwitter: @Thaboxingvoicehttps://twitter.com/thaboxingvoiceAudio only Podcast subscribe herehttps://itun.es/us/oY7JJ.cMUSIC CREDITCASH APP $Dolla Dibiase https://www.instagram.com/dolla_dibiase/?hl=en

Episodio 56 de nuestro podcast en el cual hablamos de lo ocurrido en las peleas de Gervonta Davis vs Isaac Cruz, y la de Devin Haney vs Joseph Diaz. Recuerda suscribirte en nuestro canal de YouTube y activar la

In this episode of the Fight Junkie Podcast series, we touch on the 12 round decision victory Devin Haney {27-0} was able to secure over Joseph Diaz {32-2} and where Haney goes from here. Our website: http://www.fightjunkie.com Follow Us On These Social Media Platforms: https://twitter.com/FightJunkieCom https://www.instagram.com/fight_junkie/ https://www.twitch.tv/realfightjunkie https://anchor.fm/fight-junkie https://www.tumblr.com/blog/realfightjunkie Listen To Our Podcast Here: Our podcast is live on Apple HomePod. Try saying, "Hey Siri, play the podcast Fight Junkie. Our podcast should also be live soon on Google Home. Try saying “Hey Google, play the podcast Fight Junkie Amazon Music: https://music.amazon.com/podcasts/281faea0-e592-455b-ae3c-be89ca86a0d3/Fight-Junkie Anchor: https://anchor.fm/fight-junkie Apple Podcasts: https://itunes.apple.com/us/podcast/fight-junkie/id1430819358?mt=2&uo=4 Google Podcasts: https://www.google.com/podcasts?feed=aHR0cHM6Ly9hbmNob3IuZm0vcy82NzllMDA0L3BvZGNhc3QvcnNz Spotify: https://open.spotify.com/show/7K5YtwXFO28DIwbiYNA2bd Breaker: https://www.breaker.audio/fight-junkie Pocket Casts: https://pca.st/0CZd Radio Public: https://play.radiopublic.com/fight-junkie-WRVrww Stitcher: https://www.stitcher.com/podcast/anchor-podcasts/fight-junkie Overcast: https://overcast.fm/itunes1430819358/fight-junkie Castbox: https://castbox.fm/channel/id1417240

In this episode of the Fight Junkie Podcast series, we breakdown the Devin Haney {26-0} V Joseph Diaz {32-1} match-up and go over what we feel are possible betting opportunities & the odds for each of these fighters as well as our predictions & suggested betting strategies for those picks. Information Is For Entertainment Purposes Only! Our website: http://www.fightjunkie.com Follow Us On These Social Media Platforms: https://twitter.com/FightJunkieCom https://www.instagram.com/fight_junkie/ https://www.twitch.tv/realfightjunkie https://anchor.fm/fight-junkie https://www.tumblr.com/blog/realfightjunkie Listen To Our Podcast Here: Our podcast is live on Apple HomePod. Try saying, "Hey Siri, play the podcast Fight Junkie. Our podcast should also be live soon on Google Home. Try saying “Hey Google, play the podcast Fight Junkie Amazon Music: https://music.amazon.com/podcasts/281faea0-e592-455b-ae3c-be89ca86a0d3/Fight-Junkie Anchor: https://anchor.fm/fight-junkie Apple Podcasts: https://itunes.apple.com/us/podcast/fight-junkie/id1430819358?mt=2&uo=4 Google Podcasts: https://www.google.com/podcasts?feed=aHR0cHM6Ly9hbmNob3IuZm0vcy82NzllMDA0L3BvZGNhc3QvcnNz Spotify: https://open.spotify.com/show/7K5YtwXFO28DIwbiYNA2bd Breaker: https://www.breaker.audio/fight-junkie Pocket Casts: https://pca.st/0CZd Radio Public: https://play.radiopublic.com/fight-junkie-WRVrww Stitcher: https://www.stitcher.com/podcast/anchor-podcasts/fight-junkie Overcast: https://overcast.fm/itunes1430819358/fight-junkie Castbox: https://castbox.fm/channel/id1417240

We are back with a quick show w/ Mike and Mark Luketic to help you enjoy the fights this weekend. Regular show on Sunday.Follow the substack - LukieBoxing.substack.com

Analizamos los combates de Gervonta Davis vs Isaac Cruz y Devin Haney vs Joseph Diaz. Recuerda suscribirte a nuestro canal de youtube y activar la

Knock 'Em Out the Box - Episode 20 - Vinnie "Predictions" gets his praises sung for his breakdown of the Crawford Porter fight. The boys go in-depth and discuss the fight, the outcome, and what's next for Terence Crawford. Did George Kambosos halt Teofimo Lopez's plans for domination? According to the Lopez family, he didn't. Was the Fulton Figueroa fight a fight of the year? Was it scored properly? Who will win the upcoming battles between Devin Haney and Joseph Diaz? Will Gervonta Davis shine against Isaac Cruz? Can Vincestradamus work his magic and properly predict these tilts? All that and much more on this week's Knock 'Em Out The Box. Catch us wherever you listen to podcasts and write with questions and comments at keotboxing@gmail.com

The WBC lightweight champ defends his title on Saturday live on DAZN

The lightweight division is on fire right now

Join this channel to get access to perks:https://www.youtube.com/channel/UCcKT39KR_e3ZliHe4cyC06A/joinOne Free Month of Dazn On TBV http://bit.ly/ThaBoxingVoicexDAZNhttps://www.patreon.com/ThaboxingvoiceBUY THA BOXING VOICE T-SHIRT HERE http://thaboxingvoice.com/storePLEASE SUPPORT!!! SUBSCRIBE, SHARE & LIKEPlease check out our Facebook page and hit the like button. https://www.facebook.com/Thaboxingvoiceradio GOOGLE PLUS https://plus.google.com/107960664507143008932/posts?tab=XXiWeb Sitehttp://thaboxingvoice.com/Radio show: http://www.blogtalkradio.com/thaboxingvoiceradioTwitter: @Thaboxingvoicehttps://twitter.com/thaboxingvoiceAudio only Podcast subscribe herehttps://itun.es/us/oY7JJ.cMUSIC CREDITCASH APP $Dolla Dibiase https://www.instagram.com/dolla_dibiase/?hl=en

☎️Reaction to George Kambosos Jr's Huge Upset Win

When it comes to life changing events, there is nothing quite like travel. Joseph Diaz is the co-founder of AFAR Media, and he has taken it upon himself to use travel as a way to enrich the lives of the younger generation that doesn't have the same opportunities. There's a lot to be said about going to a completely new place and truly immersing yourself in the culture, and seeing what you can do to contribute to the community.  Listen to this week's episode as he shares #hospitality insights with Dan Ryan today! Takeaways:  The hospitality world has been flipped upside down. In 2019 it was very guest centric, but today it is a two way street. It is a concept that embraces the idea of mutual benefit, and what the guest can bring to the community. A form of hospitality where you put the guest on a pedestal is limiting and creates a fear of messing up. But what the guest truly craves is connection to the place they are visiting. Travel is the best form of education. Getting young people to travel and explore the world will provide them opportunities they might not have ever had and can change their world. You need to create a message to attract people to come visit your town or location not just during tourist season, but at all times of the year. How do we continue to stay open to new experiences? The good, the bad, the ugly? We have natural tendencies to run away from things we don't like, but those experiences are just as important. The generation coming up is more in tune with their values and more open to travel and exploring other communities. Quote of the Show:   1:34 “A 2019 definition of hospitality would be one that is extremely guest centric, where it's focused on the desk, doing everything to make the guests feel welcome, feel at home. You know, there's tons of  definitions that are similar to that in our world. And the way that we're thinking about things today, hospitality for us is a two-way street. It is a concept that really embraces the idea of mutual benefit and what the guests can also contribute to the equation. You know, I think JFK, his famous ‘ask not what your country can do for you, ask what you can do for your country.' Similarly ask, ‘not what your travels can do for you; ask what your travels can do for the communities where you're traveling and the planet in which we are living.'” Links:  Joseph's Profile: https://linkedin.com/in/josephdiaz Company website: www.afar.com Twitter: @JoeDiazAFAR Shout Outs:  0:26 Independent Lodging Congress 5:09 White Lotus 9:01 “The 7 Habits of Highly Effective People” by Stephen Covey 9:45 Laura Redmond 9:49 Ben Pundole  13:42 Teach for America 14:13 Rosa Linda Elementary School in South Phoenix, AZ 16:10 JFK  16:16 Peace Corps 26:08 Reykjavik 26:09 Venice 30:20 Asheville, North Carolina 31:45 Vanuatu 36:51: Airbnb 1;04:44 Amika Moran 1;07:08 Staples Ways to Tune In:  Spotify: https://open.spotify.com/show/0A2XOJvb6mGqEPYJ5bilPX Apple Podcasts: https://podcasts.apple.com/us/podcast/defining-hospitality-podcast/id1573596386 Google Podcasts: https://podcasts.google.com/feed/aHR0cHM6Ly93d3cuZGVmaW5pbmdob3NwaXRhbGl0eS5saXZlL2ZlZWQueG1s Podbean:  https://www.defininghospitality.live/ YouTube: https://youtu.be/Bl5TRqnVWiw

The Dunwich HorrorWritten by H.P. LovecraftPerformed by Mick DarkAudio Production by Mick DarkCover Art by Joseph Diaz josephdiaz.artstation.com "The Dunwich Horror" is a 1928 short story by cult-favorite horror author H.P. Lovecraft. The story is also part of a literary universe known as the “Cthulhu Mythos.” While the work was originally published in the magazine, “Weird Tales,” it has since been printed in many other forms.“The Dunwich Horror” is the story of the Whateleys and its relation to the Dunwich Horror, which happened in Dunwich, Massachusetts in 1928. The narrator is an unnamed third person narrator. The story begins with the explanation that the Dunwich Horror was covered up by the town. The narrative then shifts to a chronological recollection.The recollection starts with the birth of Wilbur Whateley, the son of a strange albino woman, Lavinia, and an unknown father. He lived with his mother and his grandfather, Old Whateley, also known as the Wizard Whateley. The boy grew incredibly fast in terms of mental capabilities, maturity, and height. Eventually, the boy's grandfather began teaching him about the occult and bought him many occult related books. The two also began renovating their property adding rooms and removing walls as if they were hiding something.After Lavinia disappeared and Old Whatley died, the boy began to search for the grimoire known as the Necronomicon for an unknown purpose. He eventually went to Miskatonic University and met the librarian, Dr. Armitage. He asked Armitage if he could borrow the untranslated copy of the work but Armitage refused. Armitage then looked at the book and learned that Wilbur was trying to do something nefarious.Not long after, Wilbur attempted to break into the Miskatonic University library in order to steal their copy of the Necronomicon. Wilbur was killed by a guard dog. His corpse revealed his true form, witnessed by Armitage and his colleagues Rice and Morgan. It was covered in tentacles and was rather unhuman. His body then disintegrated before their eyes.Not long after, the creature known as the Dunwich Horror escaped from the Whatley home and began nightly rampages throughout the town. The professors eventually learned of this and Armitage decided that he needed to act. Through his research, Armitage discovered that a spell could vanquish the Horror.The Horror made a path towards Sentinel Hill. A few days afterwards, the professors arrived and confronted the beast. They sprayed a powder on the being, revealing it to be rather similar to a mixture of Wilbur's true horrifying form and the Whately family's human members. Armitage and the professors chanted a spell at the beast until a lightning strike caused the monster to disappear. The narrator then describes that the entire ordeal was covered up.Twitter @MICKDARKVOICEReddit https://www.reddit.com/r/MickDark/Facebook https://bit.ly/3hCdEZe#mickdark #HPLovecraft #lovecraft #cult

Knock 'Em Out the Box - Episode 9 - Vinnie is back!!!! Will Chris Colbert be a star? Does Jermell Charlo capture "All The Belts"? Will Gilberto "Zurdo" Ramirez and Sullivan Barrera cure insomnia? Joseph Diaz and Javier Fortuna look to carry Fridays DAZN card. When will Tim Tszyu come stateside? Is Jake LaMotta is a Knock 'Em Out The Box fan? Tune in and find out.

In this episode, we talk about the major upset in the first round of the main event as Conor McGregor loses to Dustin Poirier via doctor stoppage. We also talk about Gilbert Burns's victory over Stephen Thompson, Tai Tuivasa vs Greg Hardy, Ryan Hall vs Ilia Topuria, and Sean O'Malley's dominating performance over the super tough Kris Moutinho. We also talk about some boxing fights that occurred like Seniesa Estrada vs Tenkai Tsunami and Joseph Diaz vs Javier Fortuna.

The Boxing Rant podcast returns to preview Jermell Charlo vs. Brian Castano for the undisputed championship at 154-pounds. The guys discuss the post-fight from Gilberto Ramirez vs. Sullivan Barrera and Joseph Diaz vs. Javier Fortuna. Plus, Ken and Vin comment on the latest news regarding Teofimo Lopez vs. George Kambosos, and the postponement of Tyson Fury vs. Deontay Wilder 3.Thank you for subscribing to The Boxing Rant podcast.Follow us on Twitter:@VinceCummings81@KennyKeithJrContact:mailbag@theboxingrant.comOriginal music produced by DJ Chrome Bills for The Boxing Rant.Original artwork created by @Fightposium for The Boxing Rant podcast. See acast.com/privacy for privacy and opt-out information.

In this episode, we talk about the biggest card of the year, UFC 264. Conor McGregor and Dustin Poirier will fight for the third and final time and we discuss what we think will go down. We also talk about many other undercard fights in UFC 264, Seniesa Estrada vs Tsunami, Joseph Diaz vs Javier Fortuna, and a variety of other fights. 

The Boxing Rant podcast is back to preview Gilberto Ramirez vs. Sullivan Barrera and Joseph Diaz vs. Javier Fortuna. And the guys react to the latest performance by rising star Chris Colbert from this past weekend on Showtime. Kenny and Vin answer questions from their subscribers.Thank you for subscribing to The Boxing Rant podcast.Follow us onTwitter: @VinceCummings81@KennyKeithJrContact: mailbag@theboxingrant.comOriginal music produced by DJ Chrome Bills for The Boxing Rant.Original artwork created by @Fightposium for The Boxing Rant podcast.

RECAP Cory Sandhagen knocks out Frankie Edgar with a flying knee in the first roundWho does Sandhagen want to win the Yan vs Sterling fight? Who does he match up better against? Alexander Volkov knocks out Alistar Overeem in the 2nd roundWhere does Volkov fit in the heavyweight title picture? WHO YOU GOT?TRIVIA Joe vs Jared 3 rounds, each round consists of one question per person If you get the question incorrect the other person will have a chance to steal Round 1 boxing, round 2 MMA, and round 3 is a wildcard round, which will be movie, more specifically combat sports movies PREVIEW On ESPN, Joe Smith Jr. vs Maxim Vlasov for the vacant WBO light heavyweight title On DAZN, Joseph Diaz vs Shavkatdzhon Rakhimov for Diaz's IBF junior lightweight title UFC 258: Kamaru Usman vs #1 Gilbert Burns for Usman's welterweight titleOther notable fights: Women's Flyweight: #10 Maycee Barber vs #15 Alexa Grasso Middleweight: #9 Kelvin Gastelum vs #15 Ian Heinisch THE FLURRY

BERCHELT Y VALDEZ CIERRAN PREPARACION RUMBO A SU COMBATECANELO LISTO PARA YILDIRIMJO JO DIAZ HARA DEFENSA OBLIGATORIAYAMILETH MERCADO SALE CON EL PUÑO EN ALTO ANTE LA ROCKERA GUZMAN

Joseph "Jojo" Diaz is a former USA Olympian and current American professional boxer who has held the IBF Junior Lightweight Champion of the world. Jojo and Cam F Awesome were former Teammates. Find Jojo @JosephDiazJr on Twitter and Instagram.

My first Interview with a fighter. Me and Joseph Diaz sit down and talk about his career as a pro and amateur fighter and all the curve balls that come in the always crazy world of boxing

We are live at 7pm CST talking the lead in to the huge megafight tonight!  1-347-857-1060. Tonight we celebrate Cinco De Mayo weekend with another fantastic Boxing event.  Saul "Canelo" Alvarez takes on Julio Cesar Chavez, Jr. in a stacked show on HBO PPV.  The team breakdowns the build to the fight, the outcome that should happen depending on who wins, and why this fight is important to the sport. We look at what each fighter needs to do to win the contest, including how this is a perfect fight on paper for both, as their styles compliment each others, in what should make for a great slugfest. We breakdown the undercard as well, as we talk the great lead in matches, including David Lemieux vs Marco Reyes, Lucas Matthysse vs Emanuel Taylor, and Joseph Diaz vs Manuel Avila.   

We are live at 7pm CST talking the lead in to the huge megafight tonight!  1-347-857-1060. Tonight we celebrate Cinco De Mayo weekend with another fantastic Boxing event.  Saul "Canelo" Alvarez takes on Julio Cesar Chavez, Jr. in a stacked show on HBO PPV.  The team breakdowns the build to the fight, the outcome that should happen depending on who wins, and why this fight is important to the sport. We look at what each fighter needs to do to win the contest, including how this is a perfect fight on paper for both, as their styles compliment each others, in what should make for a great slugfest. We breakdown the undercard as well, as we talk the great lead in matches, including David Lemieux vs Marco Reyes, Lucas Matthysse vs Emanuel Taylor, and Joseph Diaz vs Manuel Avila. This podcast is sponsored by Anchor

We are live at 7pm CST talking the lead in to the huge megafight tonight!  1-347-857-1060. Tonight we celebrate Cinco De Mayo weekend with another fantastic Boxing event.  Saul "Canelo" Alvarez takes on Julio Cesar Chavez, Jr. in a stacked show on HBO PPV.  The team breakdowns the build to the fight, the outcome that should happen depending on who wins, and why this fight is important to the sport. We look at what each fighter needs to do to win the contest, including how this is a perfect fight on paper for both, as their styles compliment each others, in what should make for a great slugfest. We breakdown the undercard as well, as we talk the great lead in matches, including David Lemieux vs Marco Reyes, Lucas Matthysse vs Emanuel Taylor, and Joseph Diaz vs Manuel Avila. This podcast is sponsored by Anchor

We are live at 7pm CST talking the lead in to the huge megafight tonight!  1-347-857-1060. Tonight we celebrate Cinco De Mayo weekend with another fantastic Boxing event.  Saul "Canelo" Alvarez takes on Julio Cesar Chavez, Jr. in a stacked show on HBO PPV.  The team breakdowns the build to the fight, the outcome that should happen depending on who wins, and why this fight is important to the sport. We look at what each fighter needs to do to win the contest, including how this is a perfect fight on paper for both, as their styles compliment each others, in what should make for a great slugfest. We breakdown the undercard as well, as we talk the great lead in matches, including David Lemieux vs Marco Reyes, Lucas Matthysse vs Emanuel Taylor, and Joseph Diaz vs Manuel Avila. This podcast is sponsored by Anchor